{
  "title": "Paper_72",
  "abstract": "pmc Chem Sci Chem Sci 3127 chemsci SC Chemical Science 2041-6520 2041-6539 Royal Society of Chemistry PMC12489802 PMC12489802.1 12489802 12489802 10.1039/d5sc05497d d5sc05497d 1 Chemistry Gram-scale synthesis of (+)-elacestrant streamlined by iridium-catalyzed dynamic kinetic asymmetric hydrogenation of α-substituted tetralones Zong Yan a b † Zou Xiaomei c † Zhang Shaoke a † https://orcid.org/0000-0003-2276-6800 U-9458-2018 Chen Gen-Qiang a https://orcid.org/0000-0001-5700-0608 Zhang Xumu a  a Department of Chemistry, Shenzhen Grubbs Institute, Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, and Medi-Pingshan, Southern University of Science and Technology Shenzhen 518000 China zhangxm@sustech.edu.cn chengq@sustech.edu.cn zongy@sustech.edu.cn  b Department of Natural Products Chemistry, Key Lab of Chemical Biology, School of Pharmaceutical Sciences, Shandong University Jinan 250012 China  c Medical School, Shandong Xiehe University Jinan 250109 China † Yan Zong, Xiaomei Zou, and Shaoke Zhang contributed equally to this work. 26 9 2025 475402 23 7 2025 15 9 2025 26 09 2025 03 10 2025 03 10 2025 This journal is © The Royal Society of Chemistry 2025 The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ This article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence A catalytic protocol for the iridium-catalyzed dynamic kinetic resolution asymmetric hydrogenation (DKR-AH) of α-substituted tetralones to rapidly assemble various enantioenriched tetrahydronaphthols is disclosed. A wide range of enantioenriched tetrahydronaphthols were obtained in high yields and excellent stereoselectivities (up to 99% yield, up to >99.5 : 0.5 er and >20 : 1 dr). And this unique platform exhibited high efficiency for the enantioselective synthesis of (+)-elacestrant, which was approved by the FDA in 2023 for the treatment of metastatic breast cancer. Additionally, palladium-catalyzed amination of aryl chloride assisted in furnishing the gram-scale synthesis of this oral anti-tumor drug within 7 steps in 43% yield. A gram-scale synthesis of (+)-elacestrant streamlined by dynamic kinetic asymmetric hydrogenation of α-tetralones is described. National Key Research and Development Program of China 10.13039/501100012166 2021YFA1500200 National Natural Science Foundation of China 10.13039/501100001809 21991113 22171129 22302090 Science, Technology and Innovation Commission of Shenzhen Municipality 10.13039/501100010877 JCYJ20240813095106009 Basic and Applied Basic Research Foundation of Guangdong Province 10.13039/501100021171 2022B1515020055 2022A1515110093 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf yes pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pubstatus Advance Article Introduction Breast cancer has overtaken lung cancer as the most frequently diagnosed cancer worldwide, representing the leading health threat to women. 1 Fig. 1 2 Fig. 1 General information of elacestrant. Elacestrant (1) has drawn considerable attention from pharmaceutical companies as well as chemists due to its excellent therapeutic effects and huge market demand. The general strategies to access elacestrant (1) are depicted in Fig. 2A 3 N via via 4 N 5 via Fig. 2B 6 7 Fig. 2 (A) General strategies to access elacestrant (1); (B) enantioselective synthesis of 1 by DKR-AH of α-substituted tetralones (this work). Results and discussion Initially, we examined the DKR-AH with 2a as the model substrate in i Table 1 8 9 Table 1 Table 1 10 11 Table 1 Table 1 Table 1 tert t Table 1 tert t Table 1 Table 1 10 a t t t t Table 1 Reaction condition optimization for DKR-AH of 2a a  Entry Ligand Solvent Base Yield (%) Er Dr 1 L1  i  t 3 — — 2 L2  i  t 0 — — 3 L3  i  t 58 95.5 : 4.5 >20 : 1 4 b —  i  t 0 — — 5 c —  i  t 0 — — 6 L3 PhMe  t 92 96 : 4 >20 : 1 7 L3 DCM  t 45 91 : 9 >20 : 1 8 L3   t   t 99  99 : 1  >20 : 1 9 L3  t  t 96 99 : 1 >20 : 1 9 L3 MeOH  t 0 — — 10 L3 HFIP  t 0 — — 11 L3  t  t 60 95 : 5 >20 : 1 12 L3  t  t 20 95 : 5 >20 : 1 13 L3  t Na 2 3 0 — — 14 L3  t NaOH 87 98.5 : 1.5 >20 : 1  a Reaction conditions: all reactions were performed with 2a (0.2 mmol), Cat1, Cat2 or Ir/L1–L3 (0.2 mol%), and base (5 mol%) in solvent (0.4 mL) under 60 bar of H 2 1 b Cat1 was used as the catalyst. c Cat2 was used as the catalyst. Bases such as t t 2 3 t t Table 1 2 3 Table 1 Table 1 With the optimized reaction conditions in hand, we then turned our attention to the investigation of the substrate generality, and variations on the α-substitution of tetralones were first evaluated. As was shown in Scheme 1 ortho meta para Scheme 1 Substrate scope of the DKR-AH of α-substituted tetralones. a t t 2 1 b t c Before commencing the investigation for the synthesis of 1, we concentrated our efforts on the DKR-AH of elacestrant-based motifs with substrates bearing various functional groups at the 6-position of the tetralone (bottom in Scheme 1 12 With the key intermediate 3ad secured, we then concentrated our efforts on the gram-scale enantioselective synthesis of elacestrant (1). As was outlined in Scheme 2 t 13 Scheme 2 Completion of elacestrant (1) via With the key intermediate 6 in hand, we then continued our exploration of the installation of the N-containing moiety. The C–N coupling with amine seemed to be challenging with either palladium- or copper-catalytic systems, 14 ortho 15 via e.g. 2 16 15 3 g The key step of our enantioselective synthesis of elacestrant relies on the excellent enantio- and diastereo-control of the DKR-AH of α-substituted tetralones. To give a full insight into the origin of high diastereoselectivity, we calculated the transition states leading to the syn anti Fig. 3 anti −1 syn anti Fig. 3 Calculated transition states for the syn anti Conclusions In summary, we have successfully developed a highly powerful protocol for the gram-scale enantioselective synthesis of the oral anti-breast cancer drug elacestrant (1) within 7 steps in 43% overall yield, which was facilitated by the efficient iridium-catalyzed DKR-AH of α-substituted tetralones (up to 99% yield, >99.5 : 0.5 er and >20 : 1 dr for all cases) and a late-stage amination with various types of amines. The significance of this method was demonstrated by the construction of the target chirality of 1 with a substrate-to-catalyst (S/C) ratio of 10 000, showing broad potential and prospects for industrial application. The industrial enantioselective synthesis of elacestrant (1) with this synthetic route is currently underway in our laboratory and will be reported in due course. Author contributions Yan Zong and Xiaomei Zou carried out the experimental work and wrote the first draft. Xiaomei Zou and Shaoke Zhang performed experimental testing. Gen-Qiang Chen and Xumu Zhang designed the project and supervised the work. All the authors discussed the manuscript. Conflicts of interest There are no conflicts to declare. Supplementary Material SC-OLF-D5SC05497D-s001 SC-OLF-D5SC05497D-s002 X. Zhang is indebted to the financial support from the National Key R&D Program of China (2021YFA1500200), National Natural Science Foundation of China (no. 21991113), Chemistry and Chemical Engineering Guangdong Laboratory (grant no. 2011006 and 2132013), Shenzhen Key Basic Research Project (JCYJ20241202125305008), High level of special funds (G03050K003) and Innovative Team of Universities in Guangdong Province (no. 2020KCXTD016). G.-Q. Chen gratefully acknowledges the National Natural Science Foundation of China (no. 22171129), Shenzhen Science and Technology Innovation Committee (JCYJ20240813095106009), Guangdong Innovative Program (2019BT02Y335), and Guangdong Basic and Applied Basic Research Foundation (2022B1515020055) for financial support. S. Zhang appreciates the support of the National Natural Science Foundation of China (22302090) and Guangdong Basic and Applied Basic Research Foundation (2022A1515110093). Data availability The data that support the findings of this study are available from the SI or from the authors upon reasonable request. CCDC 2468465 and 2468467 contain the supplementary crystallographic data for this paper. 17 a b Supplementary information: all experimental and characterization data, NMR spectra, crystallographic data of 3l and 3w and DFT calculations. See DOI: https://doi.org/10.1039/d5sc05497d Notes and references Cao W. Chen H. Yu Y. Li N. Chen W. Chin. Med. J. 2021 134 783 791 33734139 10.1097/CM9.0000000000001474 PMC8104205 (a) Beumer J. H. Foldi J. Cancer Chemoth. Pharm. 2023 92 157 163 10.1007/s00280-023-04550-7 PMC10713198 37314500 (b) Hoy S. M. Drugs 2023 83 555 561 37060385 10.1007/s40265-023-01861-0 PMC10667141 (a) Cheng G. China Pat. 2023 (b) Hamaoka S. Kitazawa N. Nara K. Sasaki A. Kamada A. Okabe T. 2004 (c) Markey M. 2020 (d) Morini F. Calvani F. Masi M. D'Arata F. Bonaccorsi F. Ramacciotti A. Schmitz R. 2025 (e) Pan F. Yang Y. Shen C. Liu M. Liu X. Wang D. China Pat. 2025 (f) Yang Y. Huang Y. He Y. China Pat. 2024 (g) Liu Q. Yi S. Wang S. Gao H. Wang H. Wang X. China Pat. 2024 (a) Pan T. Yuan Q. Xu D. Zhang W. Org. Lett. 2024 26 5850 5855 38950380 10.1021/acs.orglett.4c02054 (b) Cheruku P. Paptchikhine A. Ali M. Neudörfl J.-M. Andersson P. G. Org. Biomol. Chem. 2008 6 366 373 18175007 10.1039/b714744a (c) Hedberg C. Källström K. Brandt P. Hansen L. K. Andersson P. G. J. Am. Chem. Soc. 2006 128 2995 3001 16506780 10.1021/ja057178b (a) Liang M.-R. Du X. Lin J. Rong N. Zhan X. Mao X. Zhuang H. Niu T. Yin Q. J. Am. Chem. Soc. 2025 147 4239 4248 39841113 10.1021/jacs.4c14200 (b) Liu R. Ding X. Lang Q. Chen G.-Q. Zhang X. Chin. Chem. Lett. 2025 36 110037 (c) Wang J.-Y. Gao C.-H. Ma C. Wu X.-Y. Ni S.-F. Tan W. Shi F. Angew. Chem., Int. Ed. 2024 63 e202316454 10.1002/anie.202316454 38155472 (d) Wu P. Yu L. Gao C.-H. Cheng Q. Deng S. Jiao Y. Tan W. Shi F. Fundam. Res. 2023 3 237 248 38932922 10.1016/j.fmre.2022.01.002 PMC11197731 (e) Wang H.-Q. Wu S.-F. Yang J.-R. Zhang Y.-C. Shi F. J. Org. Chem. 2023 88 7684 7702 36417567 10.1021/acs.joc.2c02303 (f) Chen Z. Aota Y. Nguyen H. M. H. Dong V. M. Angew. Chem., Int. Ed. 2019 58 4705 4709 10.1002/anie.201900545 PMC6501835 30740841 (g) Chen X. Fong J. Z. M. Xu J. Mou C. Lu Y. Yang S. Song B.-A. Chi Y. R. J. Am. Chem. Soc. 2016 138 7212 7215 27219078 10.1021/jacs.6b00406 (a) Li J. Ye J. Zhou J. Li J. Liu D. Zhang W. Chem. Commun. 2022 58 4905 4908 10.1039/d2cc01193j 35353102 (b) Zatolochnaya O. V. Rodríguez S. Zhang Y. Lao K. S. Tcyrulnikov S. Li G. Wang X.-J. Qu B. Biswas S. Mangunuru H. P. R. Rivalti D. Sieber J. D. Desrosiers J.-N. Leung J. C. Grinberg N. Lee H. Haddad N. Yee N. K. Song J. J. Kozlowski M. C. Senanayake C. H. Chem. Sci. 2018 9 4505 4510 29896393 10.1039/c8sc00434j PMC5958347 (a) Touge T. Sakaguchi K. Tamaki N. Nara H. Yokozawa T. Matsumura K. Kayaki Y. J. Am. Chem. Soc. 2019 141 16354 16361 31502833 10.1021/jacs.9b07297 (b) Wang F. Yang T. Wu T. Zheng L.-S. Yin C. Shi Y. Ye X.-Y. Chen G.-Q. Zhang X. J. Am. Chem. Soc. 2021 143 2477 2483 33529522 10.1021/jacs.0c13273 (c) Ye W. An Q. Gou D. Zhang Q. Xu Y. Wang J. China Pat. 2025 (a) Tao L. Yin C. Dong X.-Q. Zhang X. Org. Biomol. Chem. 2019 17 785 788 30627711 10.1039/c8ob02923g (b) Yin C. Dong X.-Q. Zhang X. Adv. Synth. Catal. 2018 360 4319 4324 (c) Yu J. Duan M. Wu W. Qi X. Xue P. Lan Y. Dong X.-Q. Zhang X. Chem. Eur. J. 2017 23 970 975 27862426 10.1002/chem.201604855 (a) Gu G. Yang T. Lu J. Wen J. Dang L. Zhang X. Org. Chem. Front. 2018 5 1209 1212 (b) Li W. Yang T. Song N. Li R. Long J. He L. Zhang X. Lv H. Chem. Sci. 2022 13 1808 1814 35282638 10.1039/d1sc05963g PMC8826950 (c) Yu J. Long J. Yang Y. Wu W. Xue P. Chung L. W. Dong X.-Q. Zhang X. Org. Lett. 2017 19 690 693 28093919 10.1021/acs.orglett.6b03862 (a) Yin C. Jiang Y. F. Huang F. Xu C. Q. Pan Y. Gao S. Chen G. Q. Ding X. Bai S. T. Lang Q. Li J. Zhang X. Nat. Commun. 2023 14 3718 37349291 10.1038/s41467-023-39375-8 PMC10287737 (b) Yu J. Huang F. Fang W. Yin C. Shi C. Lang Q. Chen G.-Q. Zhang X. Green Synth. Catal. 2022 3 175 178 (c) Zong Y. Zou X. Song J. Chen G.-Q. Zhang X. Org. Lett. 2023 25 6875 6880 37697226 10.1021/acs.orglett.3c02565 (d) You Y. e. Yin C. Xu L. Chen G.-Q. Zhang X. Green Synth. Catal. 2024 5 141 152 (a) Liu D. Gao W. Wang C. Zhang X. Angew. Chem., Int. Ed. 2005 44 1687 1689 10.1002/anie.200462178 15693046 (b) Zong Y. Gao S. Zou X. Huang Q. Chen G.-Q. Zhang X. Chin. J. Chem. 2025 43 1783 1788 (a) Chen Z. Jiang Y. Zhang L. Guo Y. Ma D. J. Am. Chem. Soc. 2019 141 3541 3549 30688450 10.1021/jacs.8b12142 (b) Xia S. Gan L. Wang K. Li Z. Ma D. J. Am. Chem. Soc. 2016 138 13493 13496 27682010 10.1021/jacs.6b08114 Xu W.-X. Peng Z. Gu Q.-X. Zhu Y. Zhao L.-H. Leng F. Lu H.-H. Nat. Synth. 2024 3 986 997 (a) Maiti D. Fors B. P. Henderson J. L. Nakamura Y. Buchwald S. L. Chem. Sci. 2011 2 57 68 22384311 10.1039/C0SC00330A PMC3289414 (b) Zhou W. Fan M. Yin J. Jiang Y. Ma D. J. Am. Chem. Soc. 2015 137 11942 11945 26352639 10.1021/jacs.5b08411 Green R. A. Hartwig J. F. Org. Lett. 2014 16 4388 4391 25133675 10.1021/ol501739g PMC4260968 Tsuboi K. Bachovchin D. A. Speers A. E. Spicer T. P. Fernandez-Vega V. Hodder P. Rosen H. Cravatt B. F. J. Am. Chem. Soc. 2011 133 16605 16616 21899313 10.1021/ja2066972 PMC3226709 (a) Zong Y. Zou X. Zhang S. Chen G.-Q. Zhang X. CCDC 2468465: Experimental Crystal Structure Determination 2025 10.5517/ccdc.csd.cc2nvmx2 (b) Zong Y. Zou X. Zhang S. Chen G.-Q. Zhang X. CCDC 2468467: Experimental Crystal Structure Determination 2025 10.5517/ccdc.csd.cc2nvmz4 ",
  "metadata": {
    "Title of this paper": "Gram-scale synthesis of (+)-elacestrant streamlined by iridium-catalyzed dynamic kinetic asymmetric hydrogenation of α-substituted tetralones",
    "Journal it was published in:": "Chemical Science",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489802/"
  }
}